The DOI matches its Crossref record; 132 of the 135 references it cites were found in a registry or an index.
Apolipoprotein C-III: understanding an emerging cardiovascular risk factor
Abstract
The concurrence of visceral obesity, insulin resistance and dyslipidaemia comprises the concept of the metabolic syndrome. The metabolic syndrome is an escalating problem in developed and developing societies that tracks with the obesity epidemic. Dyslipidaemia in the metabolic syndrome is potently atherogenic and, hence, is a major risk factor for CVD (cardiovascular disease) in these subjects. It is globally characterized by hypertriglyceridaemia, near normal LDL (low-density lipoprotein)-cholesterol and low plasma HDL (high-density lipoprotein)-cholesterol. ApoC-III (apolipoprotein C-III), an important regulator of lipoprotein metabolism, is strongly associated with hypertriglyceridaemia and the progression of CVD. ApoC-III impairs the lipolysis of TRLs [triacylglycerol (triglyceride)-rich lipoproteins] by inhibiting lipoprotein lipase and the hepatic uptake of TRLs by remnant receptors. In the circulation, apoC-III is associated with TRLs and HDL, and freely exchanges among these lipoprotein particle systems. However, to fully understand the complex physiology and pathophysiology requires the application of tracer methodology and mathematical modelling. In addition, experimental evidence shows that apoC-III may also have a direct role in atherosclerosis. In the metabolic syndrome, increased apoC-III concentration, resulting from hepatic overproduction of VLDL (very-LDL) apoC-III, is strongly associated with delayed catabolism of triacylglycerols and TRLs. Several therapies pertinent to the metabolic syndrome, such as PPAR (peroxisome-proliferator-activated receptor) agonists and statins, can regulate apoC-III transport in the metabolic syndrome. Regulating apoC-III metabolism may be an important new therapeutic approach to managing dyslipidaemia and CVD risk in the metabolic syndrome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“High ApoC-III levels were shown to increase total triglyceride levels by an accumulation of VLDL and chylomicrons [166–169]”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [168]
In the citing paper
“In hypertriglyceridemia, more VLDL particles, as measured by apoB, and larger and more triglyceride-and apoC-III-enriched lipoproteins are found (39,64,65).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [65]
In the citing paper
“Clearance of VLDL from the circulation is reduced in many patients with hypertriglyceridemia (64, 65, 73), in part due to saturation of triglyceride clearance (74).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [65]
In the citing paper
“Consequently, APOC-III is considered an independent risk factor for cardiovascular disease [30, 31].”
From The Efficacy and Safety of Plozasiran on Lipid Profile in Dyslipidemic Disorders: A Systematic Review and Meta-Analysis (2026) · cites this paper as [31]
In the citing paper
“In contrast, apo C-III is an inhibitor of LPL, but also of hepatic lipase. Plasma apo C-III concentrations correlate positively with plasma TG [19].”
From Dyslipidemia in obesity: Mechanisms and potential targets (2013) · cites this paper as [19]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Grundy, S. M., Brewer, H. B., Cleeman, J. I., Smith, S. C., & Lenfant, C. (2004) · Circulation · doi:10.1161/01.cir.0000111245.75752.c6 · Cited by 5,982
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Hokanson, J. E., & Austin, M. A. (1996) · Journal of Cardiovascular Risk · doi:10.1097/00043798-199604000-00014 · Cited by 1,706
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Insulin resistance and cardiovascular disease
Ginsberg, H. N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10762 · Cited by 1,358
Schoonjans, K., Staels, B., & Auwerx, J. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42003-6 · Cited by 1,216
Identification of a nuclear receptor that is activated by farnesol metabolites
Forman, B. M., Goode, E., Chen, J., Oro, A. E., Bradley, D. J., Perlmann, T., Noonan, D. J., Burka, L. T., McMorris, T., Lamph, W. W., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90530-8 · Cited by 1,210
PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect
Tunaru, S., Kero, J., Schaub, A., Wufka, C., Blaukat, A., Pfeffer, K., & Offermanns, S. (2003) · Nature Medicine · doi:10.1038/nm824 · Cited by 791
The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)
Garcia-Calvo, M., Lisnock, J., Bull, H. G., Hawes, B. E., Burnett, D. A., Braun, M. P., Crona, J. H., Davis, H. R., Dean, D. C., Detmers, P. A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500269102 · Cited by 670
Research works printed but not linked: 4
- Assmann, 1998, The emergence of triglycerides as a significant independent risk factor in coronary artery disease, Eur. Heart J., 19, M8
- Ginsberg, 1986, Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceriderich lipoproteins by lipoprotein lipase in vivo, J. Clin. Invest., 78, 1287, 10.1172/JCI112713 · DOI · Paper page
- Sundaram, 2007, New insights into the roles of apolipoprotein C-III in stimulating the production of hepatic VLDL, Arteriosclerosis Thrombosis Vascular Biology Annual Conference, P142
- Clavey, 1995, Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII and E, Arterioscler. Thromb. Vasc. Biol., 15, 963, 10.1161/01.ATV.15.7.963 · DOI · Paper page
Cited by
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Dyslipidemia in obesity: Mechanisms and potential targets
Klop, B., Elte, J., & Cabezas, M. (2013) · Nutrients · doi:10.3390/nu5041218 · Cited by 1,665
“Plasma apo C-III concentrations correlate positively with plasma TG [19].”
BackgroundLoss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919
Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., Sacks, F., Murad, M. H., & Stalenhoef, A. F. H. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3213 · Cited by 887
“Clearance of VLDL from the circulation is reduced in many patients with hypertriglyceridemia (64, 65, 73), in part due to saturation of triglyceride clearance (74).”
Pollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., et al. (2008) · Science · doi:10.1126/science.1161524 · Cited by 688
ATUALIZAÇÃO DA DIRETRIZ BRASILEIRA DE DISLIPIDEMIAS E PREVENÇÃO DA ATEROSCLEROSE - 2017
Faludi, A., Izar, M., Saraiva, J., Chacra, A., Bianco, H., Afiune Neto, A., Bertolami, A., Pereira, A., Lottenberg, A., Sposito, A., et al. (2017) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20170121 · Cited by 633
Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids
Adkins, Y., & Kelley, D. S. (2010) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2009.12.004 · Cited by 557
“n-3 PUFA also regulate Apo CIII through their effects on PPARα, which down-regulates Apo CIII expression [213], and NF-κb, which up-regulates Apo CIII expression [214].”
BackgroundAntisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1400283 · Cited by 528
Targeting APOC3 in the familial chylomicronemia syndrome
Gaudet, D., Brisson, D., Tremblay, K., Alexander, V. J., Singleton, W., Hughes, S. G., Geary, R. S., Baker, B. F., Graham, M. J., Crooke, R. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400284 · Cited by 491
Osei-Hyiaman, D., Liu, J., Zhou, L., Godlewski, G., Harvey-White, J., Jeong, W.-I., Bátkai, S., Marsicano, G., Lutz, B., Buettner, C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34827 · Cited by 458
“Chronic, heavy marijuana use has also been recently found to increase the plasma level of apolipoprotein C-III (22), a liver-derived plasma constituent that correlates with dyslipidemia and cardiovascular risk in the metabolic syndrome (23).”
BackgroundMolecular interactions at the surface of extracellular vesicles
Buzás, E. I., Tóth, E. Á., Sódar, B. W., & Szabó-Taylor, K. É. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0682-0 · Cited by 375
Graham, M. J., Lee, R. G., Bell, T. A., Fu, W., Mullick, A. E., Alexander, V. J., Singleton, W., Viney, N., Geary, R., Su, J., et al. (2013) · Circulation Research · doi:10.1161/circresaha.111.300367 · Cited by 377
“ApoC-III, a key regulator of plasma triglyceride levels, is a 79-aa glycoprotein, synthesized principally in the liver and, to a lesser extent, by the intestine.(21,22) Multiple apoC-III protein molecules reside on the surface of apoB-containing lipoproteins and high-density lipoproteins (HDLs), a percentage of which…”
BackgroundThe Role of Triglycerides in Atherosclerosis
Talayero, B. G., & Sacks, F. M. (2011) · Current Cardiology Reports · doi:10.1007/s11886-011-0220-3 · Cited by 355
Targeting inflammation in metabolic syndrome
Welty, F. K., Alfaddagh, A., & Elajami, T. K. (2016) · Translational Research · doi:10.1016/j.trsl.2015.06.017 · Cited by 287
“In contrast, ApoC-III is a 79-aminoacid glycoprotein synthesized by the liver and intestines and an inhibitor of LPL.57 This inhibition leads to an increase in levels of TG.58 ApoC-III also increases TG levels by stimulating the synthesis ofVLDLand preventing its breakdown by inhibiting the binding of VLDL remnants to…”
BackgroundApolipoproteins in vascular biology and atherosclerotic disease
Mehta, A., & Shapiro, M. D. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00613-5 · Cited by 273
Uremia Alters HDL Composition and Function
Holzer, M., Birner-Gruenberger, R., Stojakovic, T., El-Gamal, D., Binder, V., Wadsack, C., Heinemann, A., & Marsche, G. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010111144 · Cited by 268
Hypolipidemic effects of proanthocyanidins and their underlying biochemical and molecular mechanisms
Bladé, C., Arola, L., & Salvadó, M. (2010) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200900476 · Cited by 253
How Do Elevated Triglycerides and Low HDL-Cholesterol Affect Inflammation and Atherothrombosis?
Welty, F. K. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0400-4 · Cited by 221
“ApoC-III, a 79-amino-acid glycoprotein synthesized by the liver and intestines [31], is an inhibitor of LPL and thereby, can raise TG levels [32].”
BackgroundThe Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans
Borén, J., Packard, C. J., & Taskinen, M.-R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00474 · Cited by 196
The regulation of ApoB metabolism by insulin
Haas, M. E., Attie, A. D., & Biddinger, S. B. (2013) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.04.001 · Cited by 187
Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor
Tenenbaum, A., Klempfner, R., & Fisman, E. Z. (2014) · Cardiovascular Diabetology · doi:10.1186/preaccept-2085133501150912 · Cited by 186
“In hypertriglyceridemia, more VLDL particles, as measured by apoB, and larger and more TG- and apoC-III-enriched lipoproteins are found [49-51].”
BackgroundLipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations
Noels, H., Lehrke, M., Vanholder, R., & Jankowski, J. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00423-5 · Cited by 173
Apolipoprotein C-III: from pathophysiology to pharmacology
Norata, G. D., Tsimikas, S., Pirillo, A., & Catapano, A. L. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.07.001 · Cited by 182
“Second, apoC-III inhibits the activity of LPL [29,50], an effect that is related to its ability to prevent LPL from binding to lipids, thus resulting in decreased enzyme activity and increased susceptibility of LPL to inactivation [55].”
BackgroundInfluentialDigenio, A., Dunbar, R. L., Alexander, V. J., Hompesch, M., Morrow, L., Lee, R. G., Graham, M. J., Hughes, S. G., Yu, R., Singleton, W., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0126 · Cited by 170
“This latter study demonstrates that apoC-III also inhibits an LPL-independent pathway of TRL clearance.”
BackgroundInfluentialDual metabolic defects are required to produce hypertriglyceridemia in obese subjects
Taskinen, M.-R., Adiels, M., Westerbacka, J., Söderlund, S., Kahri, J., Lundbom, N., Lundbom, J., Hakkarainen, A., Olofsson, S.-O., Orho-Melander, M., et al. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.224808 · Cited by 153
Mendivil, C. O., Zheng, C., Furtado, J., Lel, J., & Sacks, F. M. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.197830 · Cited by 145
“This generated 4 immunofractions containing lipoproteins with: (1) none of the studied apolipoproteins (otherApos CIII ); (2) one or more of apoAII, apoCI, apoCII, or apoE but no apoCIII (otherApos CIII ); (3) apoCIII and not the others (otherApos CIII ); and (4) apoCIII and at least one of the others (otherApos CIII…”
MethodLow-Density Lipoproteins Containing Apolipoprotein C-III and the Risk of Coronary Heart Disease
Mendivil, C. O., Rimm, E. B., Furtado, J., Chiuve, S. E., & Sacks, F. M. (2011) · Circulation · doi:10.1161/circulationaha.111.056986 · Cited by 136
A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease
Kei, A. A., Filippatos, T. D., Tsimihodimos, V., & Elisaf, M. S. (2012) · Metabolism · doi:10.1016/j.metabol.2011.12.002 · Cited by 136
“[2] Ooi EM, Barrett PH, Chan DC, et al.”
BackgroundWyler von Ballmoos, M. C., Haring, B., & Sacks, F. M. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.05.002 · Cited by 134
Kaltoft, M., Langsted, A., & Nordestgaard, B. G. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa172 · Cited by 122
Demystifying the management of hypertriglyceridaemia
Watts, G. F., Ooi, E. M. M., & Chan, D. C. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.140 · Cited by 115
Self-citationApolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease
Kohan, A. B. (2015) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000136 · Cited by 128
“ApoC-III levels are themselves an independent predictor of CVD risk [34,35].”
BackgroundEstablished and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109
Khetarpal, S. A., Zeng, X., Millar, J. S., Vitali, C., Somasundara, A. V. H., Zanoni, P., Landro, J. A., Barucci, N., Zavadoski, W. J., Sun, Z., et al. (2017) · Nature Medicine · doi:10.1038/nm.4390 · Cited by 117
Postprandial lipemia as a cardiometabolic risk factor
Pirillo, A., Norata, G. D., & Catapano, A. L. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.909394 · Cited by 108
Rouland, A., Masson, D., Lagrost, L., Vergès, B. L., Gautier, T., & Bouillet, B. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01703-5 · Cited by 108
“Effect on TRL metabolism Inhibition of LPL Inhibition of remnant clearance Increased VLDL assembly and secretion [65, 67, 72] Inhibition of LPL Inhibition of remnant clearance Increased VLDL assembly and secretion [73, 164, 165]”
BackgroundTargeting RNA With Antisense Oligonucleotides and Small Interfering RNA in Dyslipidemias
Katzmann, J. L., Packard, C. J., Chapman, M. J., Katzmann, I., & Laufs, U. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.070 · Cited by 99
Apolipoprotein CIII links dyslipidemia with atherosclerosis
Kawakami, A., & Yoshida, M. (2009) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.e607 · Cited by 98
Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism
Watts, G. F., Chan, D. C., Dent, R., Somaratne, R., Wasserman, S. M., Scott, R., Burrows, S., & R. Barrett, P. H. (2017) · Circulation · doi:10.1161/circulationaha.116.025080 · Cited by 93
Self-citationIs a High HDL-Cholesterol Level Always Beneficial?
Franczyk, B., Rysz, J., Ławiński, J., Rysz-Górzyńska, M., & Gluba-Brzózka, A. (2021) · Biomedicines · doi:10.3390/biomedicines9091083 · Cited by 103
Taskinen, M., & Borén, J. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0614-1 · Cited by 104
Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA)
Brinton, E. A., & Mason, R. P. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0415-8 · Cited by 83
“ApoC-III impairs TG lipolysis and hepatic uptake of TG-rich lipoproteins, is strongly and positively related to levels of remnant lipoproteins, and appears to promote atherogenesis by these and other mechanisms [67].”
BackgroundHDL in humans with cardiovascular disease exhibits a proteomic signature
Vaisar, T., Mayer, P. S., Nilsson, E. J., Zhao, X. Q., Knopp, R. H., & Prazen, B. J. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.03.023 · Cited by 80
“It is noteworthy that apoC-III inhibits lipoprotein lipase and the hepatic uptake of triglyceride-rich lipoproteins, which might increase levels of atherogenic triglyceride-rich lipoproteins [34,35].”
BackgroundAlvi, S. S., Ansari, I. A., Ahmad, M. K., Iqbal, J., & Khan, M. S. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.116 · Cited by 78
Qamar, A., Khetarpal, S. A., Khera, A. V., Qasim, A., Rader, D. J., & Reilly, M. P. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.305415 · Cited by 84
“8 kDa) that is secreted from the liver and small intestine.(11) ApoC-III circulates in the blood on very LDLs (VLDLs), chylomicrons, and high-density lipoproteins (HDLs).”
BackgroundOral, E. A., Garg, A., Tami, J. A., Huang, E. A., O'Dea, L. S. L., Schmidt, H., Tiulpakov, A. N., Mertens, A. C., Alexander, V. J., Watts, L. M., et al. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.08.008 · Cited by 79
Lipid Lowering Drugs: Present Status and Future Developments
Ruscica, M., Ferri, N., Santos, R. D., Sirtori, C. R., & Corsini, A. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00918-3 · Cited by 73
RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia
Gaudet, D., Clifton, P., Sullivan, D., Baker, J., Schwabe, C., Thackwray, S., Scott, R., Hamilton, J., Given, B., Melquist, S., et al. (2023) · NEJM Evidence · doi:10.1056/evidoa2200325 · Cited by 71
Self-citationHypertriglyceridemia - Common Causes, Prevention and treatment Strategies
Rygiel, K. (2018) · Current Cardiology Reviews · doi:10.2174/1573403x14666180123165542 · Cited by 74
“Apo C3 inhibits the enzyme LPL, exhibits proinflammatory properties, decreases endothelial nitric oxide production, interferes with insulin signaling pathways, and facilitates atherosclerosis [16, 17].”
BackgroundTriglyceride-Rich Lipoproteins and Coronary Artery Disease Risk: New Insights From Human Genetics
Khetarpal, S. A., & Rader, D. J. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.305172 · Cited by 70
“8 kDa) secreted apolipoprotein, apoC-III, is expressed in the liver and intestine and circulates on and exchanges between TRLs and high-density lipoprotein (HDL).(31,32) Several studies have suggested that apoC-III negatively regulates LPL activity.”
BackgroundDyslipidemia of kidney disease
Attman, P., & Samuelsson, O. G. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32832dd832 · Cited by 79
Cho, K. (2009) · Molecules and Cells · doi:10.1007/s10059-009-0037-8 · Cited by 65
“ApoC-III is often considered to be an independent risk factor for coronary syndrome with inflammatory properties ( Ooi et al., 2008 ).”
BackgroundValleix, S., Verona, G., Jourde‐Chiche, N., Nédelec, B., Mangione, P. P., Bridoux, F., Mangé, A., Doǧan, A., Goujon, J., Lhomme, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms10353 · Cited by 68
“here is growing evidence that apolipoprotein C-III (apoC-III), a small exchangeable apolipoprotein carried in the circulation by VLDL and HDL 1 , is a master regulator of plasma TG homeostasis and downregulation of its expression has a cardiovasculo-protective effect 2 .”
BackgroundEmerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases
Geldenhuys, W. J., Li, L., Darvesh, A. S., & Sadana, P. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.10.007 · Cited by 71
“APOC3 is found on APOB-containing lipoproteins like VLDL and LDL but unlike APOB is much smaller (only ~9 Kda) [63].”
Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease
Ooi, E. M. M., Chan, D. T., Watts, G. F., Chan, D. C., Ng, T. W., Dogra, G. K., Irish, A. B., & Barrett, P. H. R. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m011163 · Cited by 66
Self-citationANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets
Akoumianakis, I., Zvintzou, E., Kypreos, K. E., & Filippatos, T. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00914-7 · Cited by 68
Jian, W., Edom, R. W., Wang, D., Weng, N., & Zhang, S. (2013) · Analytical Chemistry · doi:10.1021/ac3034757 · Cited by 63
Alexopoulos, A., Qamar, A., Hutchins, K., Crowley, M. J., Batch, B. C., & Guyton, J. R. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1136-3 · Cited by 73
HCV and the hepatic lipid pathway as a potential treatment target
Bassendine, M. F., Sheridan, D. A., Felmlee, D. J., Bridge, S. H., Toms, G. L., & Neely, R. D. G. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.06.004 · Cited by 77
“It has also been shown that apoCIII stimulates VLDL synthesis [18].”
Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias
Gareri, C., Polimeni, A., Giordano, S. A., Tammè, L., Curcio, A., & Indolfi, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11133884 · Cited by 64
“ApoC-III plays a key role in triglyceride metabolism, impairing the lipolysis of TRLs (triacylglycerol (triglyceride)-rich lipoproteins) by inhibiting lipoprotein lipase and the hepatic uptake of TRLs by remnant receptors [86], which has been found to be associated with coronary artery disease [87].”
BackgroundHigh-Density Lipoprotein Regulation of Mitochondrial Function
White, C. R., Datta, G., & Giordano, S. S. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-55330-6_22 · Cited by 61
Hypertriglyceridemia and Cardiovascular Diseases: Revisited
Han, S. H., Nicholls, S. J., Sakuma, I., Zhao, D. H., & Koh, K. K. (2016) · Korean Circulation Journal · doi:10.4070/kcj.2016.46.2.135 · Cited by 70
Raman fingerprints of amyloid structures
Flynn, J. D., & Lee, J. C. (2018) · Chemical Communications · doi:10.1039/c8cc03217c · Cited by 57
Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia
Adiels, M., Taskinen, M., Björnson, E., Andersson, L., Matikainen, N., Söderlund, S., Kahri, J., Hakkarainen, A., Lundbom, N., Sihlbom, C., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13744 · Cited by 55
Rocha, N. A., East, C., Zhang, J., & McCullough, P. A. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0697-3 · Cited by 54
Genetic variation in PNPLA3 but not APOC3 influences liver fat in non‐alcoholic fatty liver disease
Hyysalo, J., Stojkovic, I., Kotronen, A., Hakkarainen, A., Sevastianova, K., Makkonen, J., Lundbom, N. M. I., Rissanen, A., Krauss, R. M., Melander, O., et al. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.07045.x · Cited by 60
The emerging role of apolipoprotein C-III: beyond effects on triglyceride metabolism
Luo, M., & Peng, D. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0352-y · Cited by 56
“Chang et al. [24] case-control study CVD patients (n = 90) vs non-CVD patients (n = 200) 57.4 vs 53.4 80 % vs 48 % 17.4 vs 18.9 12.3 vs 9.4 261.9 vs 223.2 244.8 vs 224.3 37.0 vs 42.5 174.6 vs 165.5 HDL apoCIII to VLDL apoCIII ratio is considered as a more reliable marker to predict CVD (OR, 2.04; 95 % CI, 1.46–2.84; P…”
BackgroundInfluentialDelgado‐Lista, J., Pérez‐Jiménez, F., Ruano, J., Pérez‐Martínez, P., Fuentes, F. J., Criado-García, J., Parnell, L. D., García‐Ríos, A., Ordovás, J. M., & López‐Miranda, J. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m800527-jlr200 · Cited by 53
“and, hereby, plasma APOC3 concentrations are positively associated with TG concentrations(12).”
BackgroundDunbar, R. L., Nicholls, S. J., Maki, K. C., Roth, E. M., Orloff, D. G., Curcio, D., Johnson, J., Kling, D., & Davidson, M. H. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0100-8 · Cited by 52
“Elevated levels of both Apo CIII [8, 9, 11, 12] and Lp-PLA2 [28–30] have been associated with increased CVD event risk beyond that attributable to traditional risk factors.”
BackgroundEfficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients
Stein, E., Bays, H. E., Koren, M. J., Bakker-Arkema, R. G., & Bisgaier, C. L. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.08.002 · Cited by 59
ApoCIII: A multifaceted protein in cardiometabolic disease
D’Erasmo, L., Costanzo, A. D., Gallo, A., Bruckert, É., & Arca, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154395 · Cited by 53
Amar, M. J., Sakurai, T., Sakurai-Ikuta, A., Sviridov, D. O., Freeman, L. A., Ahsan, L., & Remaley, A. T. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.220418 · Cited by 51
“…phenomenon is their ability to displace apolipoprotein C-II (apoC-II), a known activator of lipoprotein lipase (LPL) (Kei et al., 2012), or they may, like apolipoprotein C-III (apoC-III), cause direct inhibition of LPL (Wang et al., 1985; Shachter et al., 1994; Jong et al., 1999; Ooi et al., 2008).”
BackgroundBallantyne, C. M., Bays, H. E., Braeckman, R. A., Philip, S., Stirtan, W. G., Doyle, R. T., Soni, P. N., & Juliano, R. A. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2016.02.008 · Cited by 47
Witztum, J. L., Gaudet, D., Arca, M., Jones, A., Soran, H., Gouni‐Berthold, I., Stroes, E. S. G., Alexander, V. J., Jones, R., Watts, L. M., et al. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.03.007 · Cited by 45
Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy
Gaudet, D., Drouin‐Chartier, J., & Couture, P. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.12.019 · Cited by 46
Dai, W., Zhang, Z., Yao, C., & Zhao, S. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1166-5 · Cited by 45
“transferred back to newly synthesized TG-enriched VLDL particles [11].”
BackgroundOoi, E. M. M., Watts, G. F., Chan, D. C., Chen, M., Nestel, P. J., Sviridov, D., & Barrett, P. H. R. (2008) · Diabetes Care · doi:10.2337/dc08-0358 · Cited by 41
“ApoC-III inhibits LPL activity and TRL remnant uptake by hepatic lipoprotein receptors (4).”
BackgroundResultInfluentialSelf-citationOlkkonen, V. M., Sinisalo, J. P., & Jauhiainen, M. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.03.019 · Cited by 42
“The classic function of apoC-III is the inhibition of LPL and hepatic lipase, resulting in marked effects on the concentrations of circulating TRL [36,37] (Fig.”
BackgroundEfficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials
Fogacci, F., Norata, G. D., Toth, P. P., Arca, M., & Cicero, A. F. G. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00836-w · Cited by 42
Proteomic Analysis of Proteins Eliminated by Low‐Density Lipoprotein Apheresis
Yuasa, Y., Osaki, T., Makino, H., Iwamoto, N., Kishimoto, I., Usami, M., Minamino, N., & Harada‐Shiba, M. (2013) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12056 · Cited by 40
“Apo C-III is known to be distributed mainly in VLDL and HDL, and secreted as a component of VLDL from the liver (25).”
BackgroundInfluentialTaniguchi, H., Tanisawa, K., Sun, X., Cao, Z., Oshima, S., Ise, R., Sakamoto, S., & Higuchi, M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1877 · Cited by 43
“ApoC-III decreases the clearance of circulating TGs by inhibiting lipoprotein lipase activity (38).”
BackgroundLopez, M. F., Sarracino, D. A., Prakash, A., Athanas, M., Krastins, B., Rezai, T., Sutton, J. N., Peterman, S. M., Gvozdyak, O., Chou, S., et al. (2012) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201100041 · Cited by 42
The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia
Gouni‐Berthold, I. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.05.003 · Cited by 40
Srivastava, R. A. K. (2023) · Cells · doi:10.3390/cells12121648 · Cited by 48
“LPL is an important player in the metabolism of TLRs [47], resulting in cardio-protection [110].”
BackgroundCalcaterra, I. L., Lupoli, R., Minno, A. D., & Minno, M. N. D. D. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13841 · Cited by 41
Heidari, A. (2020) · Advanced Science Engineering and Medicine · doi:10.1166/asem.2020.2635 · Cited by 38
Hibert, P., Mirebeau‐Prunier, D., Beseme, O., Chwastyniak, M., Tamareille, S., Pinet, F., & Prunier, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085669 · Cited by 37
“Involved in triglyceride-rich lipoprotein clearance and catabolism, ApoC-III is associated with hypertriglyceridemia, type-I diabetes, and coronary heart diseases [48–50].”
BackgroundApolipoprotein C-III and cardiovascular diseases: when genetics meet molecular pathologies
Dib, I., Khalil, A., Chouaib, R., El-Makhour, Y., & Noureddine, H. (2021) · Molecular Biology Reports · doi:10.1007/s11033-020-06071-5 · Cited by 37
Ding, Y., Wang, Y., Zhu, H., Fan, J., Yu, L., Liu, C., & Liu, E. (2010) · Transgenic Research · doi:10.1007/s11248-010-9467-5 · Cited by 36
“Clinically, apoCIII has been recognized as an independent risk factor for cardiovascular disease (Ooi et al. 2008).”
BackgroundSecondary hypertriglyceridemia in children and adolescents
Blackett, P. R., Wilson, D. P., & McNeal, C. J. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.04.006 · Cited by 36
A Pressure-dependent Model for the Regulation of Lipoprotein Lipase by Apolipoprotein C-II
Meyers, N. L., Larsson, M., Olivecrona, G., & SMALL, D. M. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.629865 · Cited by 34
“ApoC-III inhibits LPL (52-55), lipoprotein assembly and secretion (56), and lipoprotein remnant uptake (1,57) and is a strong independent predictor of cardiovascular disease (58).”
BackgroundWithin-person variation in the postprandial lipemic response of healthy adults
Ryan, M. F., Grada, C. O., Morris, C., Segurado, R., Walsh, M. C., Gibney, E. R., Brennan, L., Roche, H. M., & Gibney, M. J. (2013) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.112.047936 · Cited by 34
Okada, T., Ohama, T., Takafuji, K., Kanno, K., Matsuda, H., Sairyo, M., Zhu, Y., Saga, A., Kobayashi, T., Masuda, D., et al. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.01.002 · Cited by 33
Reimund, M., Kovrov, O., Olivecrona, G., & Lookene, A. (2017) · Journal of Lipid Research · doi:10.1194/jlr.d071787 · Cited by 32
The role of triglycerides in cardiovascular risk
Gandotra, P., & Miller, M. J. (2008) · Current Cardiology Reports · doi:10.1007/s11886-008-0079-0 · Cited by 37
Production of Apolipoprotein C-III Knockout Rabbits using Zinc Finger Nucleases
Yang, D., Zhang, J., Xu, J., Zhu, T., Fan, Y., Fan, J., & Chen, Y. E. (2013) · Journal of Visualized Experiments · doi:10.3791/50957 · Cited by 32
Olivieri, O., Martinelli, N., Baroni, M., Branchini, A., Girelli, D., Friso, S., Pizzolo, F., & Bernardi, F. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000440 · Cited by 32
“There is no doubt that until now the scientific interest has been exclusively focused on the lipid-related atherogenic and proinflammatory features of this apolipoprotein.(35) Indirect evidences from a few clinical studies regarding the thrombotic complications of CAD in the setting of secondary prevention and, more d…”
ResultSemenkovich, C. F., Goldberg, A. C., & Goldberg, I. J. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00037-7 · Cited by 38
The association of HDL-apoCIII with coronary heart disease and the effect of statin treatment on it
Xiong, X., Liu, H., Hua, L., Zhao, H., Wang, D., & Li, Y. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0129-8 · Cited by 31
“As an atherogenic factor, apoCIII exists in both HDL and apoB-lipoproteins, and transfers between them during the process of lipolysis [22–24].”
BackgroundSkulas-Ray, A. C., Alaupovic, P., Kris-Etherton, P. M., & West, S. G. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.12.001 · Cited by 30
Metadata
- Authors
- Ooi, E. M. M., Barrett, P. H. R., Chan, D. C., & Watts, G. F.
- Affiliations
- The University of Western Australia (AU)
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2008-04-14
- Volume
- 114
- Issue
- 10
- Pages
- 611-624
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- OpenAlex
- W2037283919
- Cited by
- 282
- References
- 135
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 12 · 2023: 11 · 2022: 12 · 2021: 16 · 2020: 18 · 2019: 22 · 2018: 16 · 2017: 16 · 2016: 25 · 2015: 18 · 2014: 17 · 2013: 25 · 2012: 10
- FWCI
- 2.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Science (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Funders
- National Institute of Biomedical Imaging and Bioengineering (P41EB001975)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- apolipoprotein C-III, metabolic syndrome, hypertriglyceridemia, dyslipidemia, cardiovascular risk, triglyceride-rich lipoproteins, lipoprotein lipase inhibition, atherosclerosis, PPAR agonists, statins, lipoprotein metabolism
- MeSH terms
- Animals, Humans, Insulin Resistance, Intestinal Mucosa, Liver, Risk Factors, Triglycerides, Hypertriglyceridemia, Metabolic Syndrome, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.